P53 expression correlates with low axillary tumor burden in breast cancer.

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-230013

Pau Nicolau, Paula Masó, Núria Argudo, Marta Jiménez, Ana Isabel Martínez, Ivonne Vázquez, Laura Comerma, Maria Vernet-Tomás

{"title":"P53 expression correlates with low axillary tumor burden in breast cancer.","authors":"Pau Nicolau, Paula Masó, Núria Argudo, Marta Jiménez, Ana Isabel Martínez, Ivonne Vázquez, Laura Comerma, Maria Vernet-Tomás","doi":"10.3233/BD-230013","DOIUrl":null,"url":null,"abstract":"Background: The p53 mutation in breast cancer confers a worse prognosis and is usually associated with p53 overexpression (p53+) on immunohistochemistry. Previous studies have shown that p53+ tumors could be associated with low axillary tumor burden (ATB).Objective: We aimed to evaluate the association between p53+ and ATB in a large series of breast cancers as an aid to personalizing axillary surgical treatment.Methods: We retrieved 1762 infiltrating breast carcinomas from our database that were treated with upfront surgery in Hospital del Mar from 2004 to 2018. We compared p53+ and p53-negative (p53-) tumors in terms of the percentage of cases with high ATB and overall survival. This comparison was made overall and for each immunophenotype.Results: Overall, 18.7% of breast tumors were p53+. High ATB was less common in p53+ tumors than in p53- tumors in the luminal B-Her2-negative immunophenotype (6.2% versus 16.9%, respectively, P = 0.025), but not in the other immunophenotypes or overall. Overall survival was worse in patients with p53+ breast cancer (P = 0.002).Conclusion: p53+ breast cancers were associated with worse overall survival. However, low ATB was more common in these tumors than in p53- tumors in the luminal B-Her2-negative subtype. Information on p53 expression could be of use to predict ATB in some breast cancer tumors.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"429-435"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-230013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The p53 mutation in breast cancer confers a worse prognosis and is usually associated with p53 overexpression (p53+) on immunohistochemistry. Previous studies have shown that p53+ tumors could be associated with low axillary tumor burden (ATB).

Objective: We aimed to evaluate the association between p53+ and ATB in a large series of breast cancers as an aid to personalizing axillary surgical treatment.

Methods: We retrieved 1762 infiltrating breast carcinomas from our database that were treated with upfront surgery in Hospital del Mar from 2004 to 2018. We compared p53+ and p53-negative (p53-) tumors in terms of the percentage of cases with high ATB and overall survival. This comparison was made overall and for each immunophenotype.

Results: Overall, 18.7% of breast tumors were p53+. High ATB was less common in p53+ tumors than in p53- tumors in the luminal B-Her2-negative immunophenotype (6.2% versus 16.9%, respectively, P = 0.025), but not in the other immunophenotypes or overall. Overall survival was worse in patients with p53+ breast cancer (P = 0.002).

Conclusion: p53+ breast cancers were associated with worse overall survival. However, low ATB was more common in these tumors than in p53- tumors in the luminal B-Her2-negative subtype. Information on p53 expression could be of use to predict ATB in some breast cancer tumors.

查看原文本刊更多论文

P53 表达与乳腺癌低腋窝肿瘤负荷相关。

背景：乳腺癌中的 p53 基因突变会导致预后恶化，通常与免疫组化中 p53 基因的过度表达（p53+）有关。先前的研究表明，p53+肿瘤可能与低腋窝肿瘤负荷（ATB）有关：我们旨在评估大量乳腺癌患者中 p53+ 与腋窝肿瘤负荷（ATB）之间的关系，以帮助进行个性化的腋窝手术治疗：我们从数据库中检索了2004年至2018年在德尔马医院接受前期手术治疗的1762例浸润性乳腺癌。我们比较了p53+和p53阴性（p53-）肿瘤的高ATB病例比例和总生存率。这一比较既针对总体情况，也针对每种免疫表型：结果：总体而言，18.7%的乳腺肿瘤为p53+。在管腔B-Her2阴性免疫分型中，p53+肿瘤的高ATB发生率低于p53-肿瘤（分别为6.2%和16.9%，P = 0.025），但在其他免疫分型或总体中并不常见。结论：P53+乳腺癌患者的总生存率较低（P = 0.002）。结论：p53+乳腺癌与较差的总生存率有关，但与p53-肿瘤相比，低ATB在管腔B-Her2阴性亚型肿瘤中更为常见。p53表达信息可用于预测某些乳腺癌肿瘤的ATB。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.